Compare Abbott Laboratories (ABT) vs NRG Energy Inc (NRG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs NRG Energy Inc — how do they compare? Abbott Laboratories trades at $95.37 (market cap $166.94B), while NRG Energy Inc trades at $136.39 (market cap $29.12B). The key difference: Abbott Laboratories is far larger — about 5.7× NRG Energy Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | NRG | |
|---|---|---|
Market Cap | $166.94B | $29.12B |
Sector | Health | Utilities |
52-Week High | $136.62 | $184.03 |
52-Week Low | $82.57 | $120.65 |
Enterprise Value | $193.69B | $52.95B |
Dividend Yield | 2.63% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
NRG Energy trades at $138.01, up 0.96% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $30.71B revenue and $864M net income, though Q1 2026 earnings missed expectations. Valuation metrics show a high P/E ratio of 154.96 but attractive P/S of 0.87. Recent corporate actions include a $0.48 dividend payment in May 2026.
Outlook remains cautiously optimistic with 64% analyst buy ratings, though elevated debt levels and recent earnings miss pose risks. The stock offers value through reasonable sales multiples and dividend income, but investors should monitor execution on 2026 EBITDA guidance of $5.3-5.8B and manage exposure to energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
